{"title":"Empagliflozin Promotes Natriuresis in Diabetic Patients with Cirrhotic Refractory Ascites: A Proof-of-Concept Study.","authors":"Rongya Shi, Yuan Gao, Yunyi Gao, Longzhen Zhou, Wei Qin, Feng Zhao, Jianru Jia, Zhongjie Hu","doi":"10.15403/jgld-6897","DOIUrl":"10.15403/jgld-6897","url":null,"abstract":"<p><strong>Background and aims: </strong>Interventional studies directly targeting natriuresis in refractory cirrhotic ascites are scarce, and no prospective study has examined whether sodium-glucose transporter 2 (SGLT2) inhibitor-induced glucosuria is associated with changes in renal sodium handling. We conducted a randomized, open-label, proof-of-concept study to characterize the short-term natriuretic response to empagliflozin in patients with diabetes and refractory ascites Methods: Adults with type 2 diabetes, decompensated cirrhosis, and refractory ascites were randomized 1:1 to empagliflozin 10 mg once daily plus standard care or standard care alone for 10 days. The primary outcome was the between-group difference in mean change in fractional excretion of sodium (FENa, %) from baseline (Day 0) to the mean of post-baseline Days 1, 3, 7, and 10, estimated using a linear mixed-effects model. Key secondary outcomes included 24-hour urinary sodium excretion, 24-hour urine volume, and mean daily paracentesis volume.</p><p><strong>Results: </strong>Twenty-one participants were randomized (empagliflozin n=10; control n=11). In the empagliflozin group, the between-group difference in mean change in FENa from baseline to the post-baseline mean (days 1, 3, 7, and 10) was +0.44 percentage points (95%CI: 0.05-0.83; p=0.029). Empagliflozin increased 24-hour urinary sodium excretion by +92.1 mmol/24 h (95%CI: 47.1-137.2) and 24-hour urine volume by + 822 mL/24 h (95%CI: 403-1240) versus control. Mean daily paracentesis volume was 0.6 ± 0.4 L/day with empagliflozin and 1.3 ± 0.6 L/day with control (mean difference -0.70 L/day, 95%CI: -1.17 to -0.23). No serious adverse events occurred.</p><p><strong>Conclusions: </strong>In this open-label, proof-of-concept study, empagliflozin was associated with improved short-term natriuretic indices over 10 days in diabetic patients with decompensated cirrhosis and refractory ascites, without serious adverse events. Larger, blinded, longer-term trials are warranted to confirm these preliminary findings.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"393-399"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Maria Ciurdorean, Paul Chiroi, Daniel Gabriel Cosma, Mihai Dumitru Porojan, Ioana Rusu, Stefan Strilciuc, Ioana Berindan-Neagoe, Nadim Al Hajjar
{"title":"The Coding and Non-Coding Genomic Landscape of Hepatocellular Carcinoma: Etiological Risk Factors and their Current Clinical Implications.","authors":"Ana Maria Ciurdorean, Paul Chiroi, Daniel Gabriel Cosma, Mihai Dumitru Porojan, Ioana Rusu, Stefan Strilciuc, Ioana Berindan-Neagoe, Nadim Al Hajjar","doi":"10.15403/jgld-7552","DOIUrl":"https://doi.org/10.15403/jgld-7552","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the most common liver malignancy and a leading cause of cancer mortality, with burden projected to rise substantially by 2040. Its poor prognosis reflects the timing of diagnosis: HCC develops silently against chronic liver disease, and six-monthly ultrasound with alpha-fetoprotein remains insensitive in the early stages. Two developments have reshaped molecular understanding of this heterogeneous cancer. Large-scale sequencing established that the somatic landscape is not etiology-agnostic. The driver hierarchy is dominated by TERT, TP53, and CTNNB1; exposure-specific mutational signatures; and structural events such as hepatitis B virus integration, all of which differ systematically by upstream cause. In parallel, a dense non-coding regulatory layer has been shown to intersect with the core processes of hepatocarcinogenesis. These layers have largely been reviewed in isolation. Here, we integrate them, organize the coding and non-coding genomic architecture of HCC by etiological risk factor, and appraise the contributions of each to clinical decision-making. Etiological patterning is asymmetric - well-established at the coding layer but not yet demonstrated at the non-coding layer, where assignments derive from single-etiology cohorts compared across studies, platforms, and normalization strategies. Cutting across both layers are convergent nodes shared by all causes, most clearly depletion of the hepatoprotective microRNA-122, a marker of convergence rather than specificity. We then assess the clinical interface: multi-analyte serum scores and methylation-based cell-free DNA now outperform ultrasound for early detection in prospective cohorts, yet none is guideline-endorsed, and no circulating non-coding RNA has reached prospective validation. The near-term clinical yield of this field lies in risk stratification, not molecularly guided therapy.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"455-468"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cecal Volvulus Presenting a Kidney-shaped Appearance with the Whirl Sign.","authors":"Masayoshi Nagahama, Daijiro Kagawa, Akira Hokama","doi":"10.15403/jgld-6728","DOIUrl":"https://doi.org/10.15403/jgld-6728","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"326"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Michele Ronza, Teresa Letizia Di Gennaro, Paola Gagliardi, Stefania Tamburrini, Giovanni Giordano
{"title":"Mesenteric artery vasospasm in shock patient with high-output heart failure due to renal cell carcinoma bone metastasis: CT findings.","authors":"Francesco Michele Ronza, Teresa Letizia Di Gennaro, Paola Gagliardi, Stefania Tamburrini, Giovanni Giordano","doi":"10.15403/jgld-6874","DOIUrl":"https://doi.org/10.15403/jgld-6874","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"325"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The \"India ink sign\" in the liver: chemical shift imaging findings in hepatic angiomyolipoma.","authors":"Jun Obara, Akio Tamura, Kunihiro Yoshioka","doi":"10.15403/jgld-6979","DOIUrl":"https://doi.org/10.15403/jgld-6979","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"500-501"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dorien Oomkens, Lotte Hazeleger, Daniëlle Van der Horst, Marjolijn Duijvestein
{"title":"Patient Perspectives on Climate Change and Sustainable Healthcare Practices: A Cross-Sectional Survey Study in Patients with Inflammatory Bowel Disease.","authors":"Dorien Oomkens, Lotte Hazeleger, Daniëlle Van der Horst, Marjolijn Duijvestein","doi":"10.15403/jgld-6908","DOIUrl":"https://doi.org/10.15403/jgld-6908","url":null,"abstract":"<p><strong>Background and aims: </strong>In the management of inflammatory bowel disease (IBD), resource-intensive procedures, such as endoscopy and treatment with biologics, substantially increase the environmental footprint. Understanding patients' perceptions on sustainable healthcare is crucial to develop climate-friendly policies. We explored perspectives on climate change and healthcare in patients with IBD using a cross-sectional survey.</p><p><strong>Methods: </strong>A web-based questionnaire was distributed to the Crohn and Colitis Netherlands panel and shared on their social platforms. The questionnaire included 27 items covering climate-related knowledge, concerns, sustainable behavior, the healthcare system's role in climate change, opinions on sustainable treatment alternatives, demographics, and IBD history. Descriptive statistics were used to summarize patient characteristics and responses. Cluster analysis was performed to identify subgroups with similar perspectives.</p><p><strong>Results: </strong>The analysis included 498 responses. A majority (72.5%) expressed concerns about climate change and 78.1% engaged in sustainable behaviors. Whilst 58.4% of patients preferred not to receive background information on sustainability when choosing between treatments, 71.3% would opt for the most sustainable treatment, 85.7% support reusable medical materials, and 77.1% would be willing to adjust their current IBD treatment to a more sustainable option. Support for sustainable healthcare practices was more divided when measures involved personal inconvenience. We identified three clusters with varying perspectives on sustainable healthcare practices. In the cluster with the most positive perspective on climate-friendly healthcare, patients were more often higher-educated, had more baseline knowledge on climate change, and already made sustainable choices in their daily life.</p><p><strong>Conclusions: </strong>IBD patients are concerned about climate change and generally support sustainable healthcare practices, provided these do not compromise their health or cause personal inconvenience.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"35 3","pages":"363-369"},"PeriodicalIF":2.0,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}